A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study - Archive ouverte HAL Access content directly
Journal Articles American Journal of Hematology Year : 2015

A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study

(1) , (2) , (3) , (4) , (5, 6, 7) , , , (8) , (9) , , (10) , , (11) , (12) , (13) , (14) , (15, 16) , (17) , (18) , (19) , , , , (20, 1) , (21, 22)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Mario Ojeda-Uribe
  • Function : Author
Caroline Bonmati
  • Function : Author
Pierre Bories
Chantal Himberlin
  • Function : Author
Philippe Rousselot
Marie C. Béné
  • Function : Author
David Liens
  • Function : Author
Yann Godfrin
  • Function : Author
Hervé Dombret

Abstract

PURPOSE: The GRASPALL/GRAALL-SA2-2008 Phase II trial evaluated the safety and efficacy of L-asparaginase encapsulated within erythrocytes (GRASPA®) in patients ≥ 55 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. FINDINGS: Thirty patients received escalating doses of GRASPA® on Day 3 and 6 of induction Phases 1 and 2. The primary efficacy endpoint was asparagine depletion \textless 2 µmol/L for at least 7 days. This was reached in 85 and 71% of patients with 100 and 150 IU/kg respectively but not with 50 IU/kg. Grade 3/4 infection, hypertransaminasemia, hyperbilirubinemia and deep vein thrombosis occurred in 77, 20, 7, and 7% of patients, respectively. No allergic reaction or clinical pancreatitis was observed despite 17% of Grade 3/4 lipase elevation. Anti-asparaginase antibodies were detected in 50% of patients and related to a reduction in the duration of asparagine depletion during induction Phase 2 without decrease of encapsulated L-asparaginase activity. Complete remission rate was 70%. With a median follow-up of 42 months, median overall survival was 15.8 and 9.7 months, in the 100 and 150 IU/kg cohorts respectively. CONCLUSIONS: The addition of GRASPA®, especially at the 100 IU/kg dose level, is feasible in elderly patients without excessive toxicity and associated with durable asparagine depletion. (clinicaltrials.gov identifier NCT01523782)

Dates and versions

hal-01237093 , version 1 (02-12-2015)

Identifiers

Cite

Mathilde Hunault-Berger, Thibaut Leguay, Françoise Huguet, Stéphane Leprêtre, Eric Deconinck, et al.. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study. American Journal of Hematology, 2015, 90 (9), pp.811--818. ⟨10.1002/ajh.24093⟩. ⟨hal-01237093⟩
199 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More